Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer.
作者信息
Zhao Hong, Li Rong, Wang Xiaoyan, Lu Xin, Hu Min, Zhang Jinbin, Zhao Xia, Song Xiaoqin, Liu Yangyang
机构信息
Department of Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, No. 56 Xinjian South Road, Yingze District, Taiyuan City, Shanxi Province, China.
Department of Gynecology, Shanxi Cancer Hospital, Taiyuan, China.
出版信息
J Ovarian Res. 2021 Feb 19;14(1):37. doi: 10.1186/s13048-021-00785-1.
Abstract
摘要
相似文献
1
Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer.撤稿说明：阿帕替尼联合紫杉醇（白蛋白结合型）在铂耐药卵巢癌中的作用
J Ovarian Res. 2021 Feb 19;14(1):37. doi: 10.1186/s13048-021-00785-1.
2
Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study.阿帕替尼治疗铂耐药复发性上皮性卵巢癌的疗效与安全性：一项真实世界研究
Drug Des Devel Ther. 2019 Nov 15;13:3913-3918. doi: 10.2147/DDDT.S220847. eCollection 2019.
3
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.阿帕替尼联合依托泊苷口服治疗铂耐药或铂抵抗复发性卵巢癌（AEROC）的Ⅱ期、单臂、前瞻性研究。
Lancet Oncol. 2018 Sep;19(9):1239-1246. doi: 10.1016/S1470-2045(18)30349-8. Epub 2018 Aug 3.
4
Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases.阿帕替尼联合拓扑替康用于铂耐药复发性卵巢癌患者的多线治疗：三例报告
Onco Targets Ther. 2018 Apr 6;11:1989-1995. doi: 10.2147/OTT.S158141. eCollection 2018.
5
Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study.阿帕替尼联合依托泊苷治疗铂耐药复发性上皮性卵巢癌患者的疗效和安全性：一项回顾性研究
J Cancer. 2020 Jul 9;11(18):5353-5358. doi: 10.7150/jca.45547. eCollection 2020.
6
Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.低剂量阿帕替尼治疗铂耐药或铂抵抗复发性卵巢癌患者的疗效和安全性：一项单中心回顾性研究。
Cancer Med. 2020 Aug;9(16):5899-5907. doi: 10.1002/cam4.3282. Epub 2020 Jul 6.
7
Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.阿帕替尼维持治疗铂耐药复发性卵巢癌的疗效及文献复习。
Cancer Biol Ther. 2018;19(12):1088-1092. doi: 10.1080/15384047.2018.1491500. Epub 2018 Aug 15.
8
Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial.脂肪组织面积作为评估阿帕替尼治疗铂耐药卵巢癌疗效的预测因子：AEROC 试验的探索性影像学生物标志物分析。
BMC Med. 2020 Oct 5;18(1):267. doi: 10.1186/s12916-020-01733-4.
9
A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.阿帕替尼治疗复发性上皮性卵巢癌的 II 期研究。
Gynecol Oncol. 2018 Feb;148(2):286-290. doi: 10.1016/j.ygyno.2017.12.013. Epub 2017 Dec 18.
10
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.帕唑帕尼联合每周紫杉醇与单独每周紫杉醇治疗铂耐药或铂难治性晚期卵巢癌（MITO 11）：一项随机、开放标签、2 期试验。
Lancet Oncol. 2015 May;16(5):561-8. doi: 10.1016/S1470-2045(15)70115-4. Epub 2015 Apr 14.
引用本文的文献
1
Mechanism of microRNA-152-3p-Mediated Regulation of Autophagy and Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells.微小RNA-152-3p介导的紫杉醇耐药卵巢癌细胞自噬及敏感性调控机制
Onco Targets Ther. 2025 Feb 4;18:179-197. doi: 10.2147/OTT.S485100. eCollection 2025.
本文引用的文献
1
The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer.阿帕替尼联合紫杉醇（铝结合型）在铂耐药卵巢癌中的作用。
J Ovarian Res. 2020 Sep 21;13(1):113. doi: 10.1186/s13048-020-00719-3.
Zotero 插件